Cancer Center Administration

癌症中心管理

基本信息

批准号：
10411075
负责人：
Laura Adams
金额：
$ 23.71万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-06-04 至 2027-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10411075
关键词：
Achievement Adherence Advocacy Animals Applications Grants Appointment Award Basic Science COVID-19 pandemic Cancer Biology Cancer Center Cancer Center Support Grant Cancer Research Infrastructure Catchment Area Cell Therapy Child Health Clinical Clinical Data Clinical Protocols Clinical Research Clinical Sciences Collaborations Communication Communities Community Outreach Data Doctor of Philosophy Early Diagnosis Evaluation Event Faculty Faculty Recruitment Fostering Foundations Funding Future Goals Grant Healthcare Healthcare Systems Hematologic Neoplasms Human Resources Infrastructure Infusion procedures Institutes Institution Intervention Lead Leadership Malignant Neoplasms Mission Modeling Nodal Office of Administrative Management Organizational Culture Outcome Parents Patients Performance Persons Pilot Projects Population Sciences Positioning Attribute Process Program Development Program Evaluation Radiobiology Reporting Research Research Institute Research Personnel Research Training Resource Sharing Resources Schools Science Seeds Services Shelter facility Strategic Planning Structure Therapeutic Time Tissue Procurements Training and Education Translational Research Universities Update Writing acronyms anticancer research base cancer clinical trial cancer imaging cancer immunotherapy cancer stem cell community engagement community partnership data management diversity and inclusion experience health equity imaging detection innovation medical schools meetings member operation programs recruit success treatment trial tumor virtual

项目摘要

PROJECT SUMMARY During this funding period the Stanford Cancer Institute (SCI) leveraged its potential as a newly designated comprehensive center. SCI achievements were supported by an experienced and highly-productive SCI administrative team (SCI-A), which broadened its collective contribution to high-impact and collaborative science under the direction of new (2018) SCI Director, Steven Artandi, MD, PhD, and new (2017) Associate Director for Administration and Strategy, Laura Adams, BS. Achievements of SCI-A during this funding period include: 1) seamless management of operations and a fully remote administrative workforce during COVID-19 pandemic; 2) major contributions to a new SCI Strategic Plan which, for the first time, integrates the research, educational and clinical missions of the enterprise (2019); 3) support for the appointment of a Director, Deputy Director, and 9 new Associate Directors, 6 of whom were also new recruitments led by the SCI; 4) transformation of the SCI- A structure; 5) advocacy efforts resulting in a 378% increase ($2.7M to $12.9M) in annual funding from the three principal entities within the parent institution; 6) management of an infusion of new institutional resources provided with Artandi’s recruitment, including additional commitments to faculty recruitment, space, and financial resources; 7) financial and administrative support for the rebuilding of Population Sciences; 8) restructuring and reinvigorating components of the Community Outreach and Engagement (COE) foundation and extensive review of SCI catchment area data; 9) expanding services and creating infrastructure for Cancer Research Training and Education Coordination (CRTEC); 10) impactful integration of the Cancer Clinical Trials Office (CCTO) within the SCI, resulting in expanded organizational prominence to more effectively advance broad CCTO initiatives; 11) assumption of financial oversight for Stanford School of Medicine’s (SOM) contractual relationship with the Parker Institute for Cancer Immunotherapy (PICI) and the new Center for Cancer Cell Therapy (CCCT); 12) assumption of management for the SOM-wide Emerson Collective Cancer Research Awards; 13) strategic review and resulting restructuring of the SCI Research Programs, and 14) management of an 89% increase (170 to 321) in staff positions. SCI-A supports the SCI’s research spectrum of basic, clinical, translational, and population science and serves 300 members, 7 SCI Research Programs, and 11 SCI Shared Resources. In 2020, SCI-A managed over $49M in revenue, up 79% (from $27.5M) this funding period. SCI-A now provides integrated financial and administrative oversight of the CCTO, which facilitated the accrual of 670 patients to interventional treatment trials in 2020 in the midst of the COVID-19 pandemic. Advancing the SCI’s mission through highly effective administrative management, strategic program planning, and centralized customer-focused services, SCI-A supports the SCI’s Director, Deputy Director, Senior Leadership Cabinet, Research Program Leaders, Shared Resource Directors, Executive Committee, External and Internal Advisory Boards, Community Advisory Board and other community partners, members, and trainees.

项目概要在此资助期间，斯坦福癌症研究所 (SCI) 发挥了其作为新指定研究中心的潜力 SCI 成果得到了经验丰富且高产的 SCI 的支持。管理团队（SCI-A），扩大了对高影响力和协作科学的集体贡献在新任 (2018) SCI 主任 Steven Artandi（医学博士、哲学博士）和新任 (2017) 副主任的指导下管理和战略领域，Laura Adams，BS。在此资助期间，SCI-A 取得的成就包括： 1) COVID-19 大流行期间的无缝运营管理和完全远程的管理人员； 2) 对新的 SCI 战略计划做出重大贡献，该计划首次将研究、教育和企业的临床任务（2019）；3）支持任命一名主任、副主任和 9 名新副董事，其中 6 名也是由 SCI 领导新招聘的；4） SCI 的转型；一个结构；5) 宣传工作使三者的年度资助增加了 378%（270 万美元至 1290 万美元）母机构内的主要实体； 6) 管理新机构资源的注入 Artandi 的招聘提供了额外的承诺，包括对教师招聘、空间和财政资源；7）重建人口科学的财政和行政支持；重组和重振社区外展和参与 (COE) 基金会的组成部分对 SCI 流域数据进行广泛审查；9) 扩大癌症服务并创建基础设施研究培训和教育协调 (CRTEC)；10) 癌症临床试验的有效整合 SCI 内的办公室 (CCTO)，从而扩大了组织的重要性，以更有效地推进广泛的 CCTO 举措；11) 对斯坦福大学医学院 (SOM) 进行财务监督与帕克癌症免疫治疗研究所 (PICI) 和新的癌症中心建立合同关系细胞疗法 (CCCT)；12) 负责 SOM 范围内的艾默生集体癌症研究奖励；13) SCI 研究项目的战略审查和由此产生的重组，以及 14) 的管理 SCI-A 职位增加了 89%（170 至 321），支持 SCI 的基础、临床、研究领域。转化和人口科学，服务于 300 名会员、7 个 SCI 研究项目和 11 个 SCI 共享项目 2020 年，SCI-A 的收入超过 4900 万美元，在本轮融资期间增长了 79%（从 2750 万美元）。现在为 CCTO 提供综合财务和行政监督，这促进了 670 2020 年在 COVID-19 大流行期间对患者进行介入治疗试验。通过高效的行政管理、战略计划规划和集中管理来完成使命以客户为中心的服务，SCI-A 支持 SCI 的主任、副主任、高级领导内阁、研究项目负责人、共享资源总监、执行委员会、外部和内部咨询委员会、社区咨询委员会和其他社区合作伙伴、成员和学员。